334 related articles for article (PubMed ID: 26867651)
1. Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report.
Tian Y; Wang R; Liu L; Ma C; Lu Q; Yin F
BMC Musculoskelet Disord; 2016 Feb; 17():72. PubMed ID: 26867651
[TBL] [Abstract][Full Text] [Related]
2. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
3. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.
Chávez-Valencia V; Arce-Salinas CA; Espinosa-Ortega F
J Clin Densitom; 2014; 17(4):484-9. PubMed ID: 24613450
[TBL] [Abstract][Full Text] [Related]
4. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
5. Unilateral uveitis with vitreous haze following zoledronic Acid therapy for osteoporosis.
Freitas-Neto CA; de Oliveira Fagundes WB; Ribeiro M; Pacheco KD; Freitas LG; Ávila MP
Semin Ophthalmol; 2015 May; 30(3):232-4. PubMed ID: 24168214
[TBL] [Abstract][Full Text] [Related]
6. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
Hadji P; Gamerdinger D; Spieler W; Kann PH; Loeffler H; Articus K; Möricke R; Ziller V
Osteoporos Int; 2012 Feb; 23(2):625-33. PubMed ID: 21442459
[TBL] [Abstract][Full Text] [Related]
7. The incidence of acute anterior uveitis after intravenous zoledronate.
Patel DV; Horne A; House M; Reid IR; McGhee CN
Ophthalmology; 2013 Apr; 120(4):773-6. PubMed ID: 23290982
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Sánchez A; Blanco R
Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
[No Abstract] [Full Text] [Related]
10. Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.
Hadji P; Ziller V; Gamerdinger D; Spieler W; Articus K; Baier M; Moericke R; Kann PH
Osteoporos Int; 2012 Jul; 23(7):2043-51. PubMed ID: 22086310
[TBL] [Abstract][Full Text] [Related]
11. [Osteoporosis and bisphosphonates].
Zuber MA
Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
[No Abstract] [Full Text] [Related]
12. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
[TBL] [Abstract][Full Text] [Related]
13. Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature.
Umunakwe OC; Herren D; Kim SJ; Kohanim S
Digit J Ophthalmol; 2017; 23(4):18-21. PubMed ID: 29403337
[TBL] [Abstract][Full Text] [Related]
14. Yearly zoledronic acid in postmenopausal osteoporosis.
Karam R; Camm J; McClung M
N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529
[No Abstract] [Full Text] [Related]
15. Annual zoledronic acid for osteoporosis.
BMJ Group
Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
[TBL] [Abstract][Full Text] [Related]
16. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
[TBL] [Abstract][Full Text] [Related]
17. Acute anterior uveitis following zoledronic acid infusion for osteoporosis.
Belliveau MJ; Almeida DR; Urton TE
Can J Ophthalmol; 2012 Oct; 47(5):e22-3. PubMed ID: 23036555
[No Abstract] [Full Text] [Related]
18. Anterior uveitis complicating zoledronic acid infusion.
Colucci A; Modorati G; Miserocchi E; Di Matteo F; Rama P
Ocul Immunol Inflamm; 2009; 17(4):267-8. PubMed ID: 19657981
[TBL] [Abstract][Full Text] [Related]
19. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
Boonen S; Sellmeyer DE; Lippuner K; Orlov-Morozov A; Abrams K; Mesenbrink P; Eriksen EF; Miller PD
Kidney Int; 2008 Sep; 74(5):641-8. PubMed ID: 18509324
[TBL] [Abstract][Full Text] [Related]
20. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
